How to decide who to treat

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 6, 2009, Pages 711-726

  Kanis, J A ^a   McCloskey, E V ^a,b   Johansson, H ^a   Strom, O ^a   Borgstrom, F ^a   Oden, A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

case finding; clinical guidelines; fracture probability; FRAX; intervention threshold

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; GENERIC DRUG; GLUCOCORTICOID; HORMONE; PREDNISOLONE; RISEDRONIC ACID; VITAMIN D;

ALGORITHM; BODY MASS; BONE DENSITY; BREAST CANCER; CALCIUM INTAKE; CASE FINDING; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG COST; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH ECONOMICS; HIGH RISK PATIENT; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; OSTEOLYSIS; OSTEOPOROSIS; PATIENT ASSESSMENT; PATIENT COMPLIANCE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; REFERENCE VALUE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY; SPINE FRACTURE; TREATMENT DURATION; TREATMENT INDICATION; ULCERATIVE COLITIS; VERTEBRA FRACTURE; WRIST FRACTURE;

FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY; RISK FACTORS;

EID: 71949090978     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.09.002     Document Type: Review

References (71)

1. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 359 (2002) 2018-2026
2. Boonen S., Body J.J., Boutsen Y., et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16 (2005) 239-254
3. Kanis J.A., and on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre (2008), University of Sheffield, UK
4. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series, 843 (1994), WHO, Geneva
5. Riggs B.L., and Melton L.J. The prevention and treatment of osteoporosis. New Engl J Med 327 (1992) 620-627
6. Kanis J.A. Use of calcium in the management of osteoporosis. Bone 24 (1999) 279-290
7. Johnell O., Stenbeck M., Rosen M., et al. Therapeutic strategies in the prevention of hip fracture with drugs affecting bone metabolism. Bone 14 supp 1 (1993) 85-87
8. Marshall D.A., Sheldon T.A., and Jonsson E. Recommendations for the application of bone density measurement. Int J Technol Assess Health Care 13 (1997) 411-419
9. Pitt F.A., Lloyd-Jones M., Brazier J.E., et al. The costs and benefits of screening for and preventing osteoporosis in Trent Region: a report of the Trent Regional Osteoporosis Working Party. Trent Health (UK) (1990)
10. Swedish Council on Technology Assessment in Health Care (SBU). Bone density measurement - a systematic review. J Intern Med Suppl 739 (1997) 241
11. Cummings S.R., and Black D. Should perimenopausal women be screened for osteoporosis?. Ann Int Med 104 (1986) 817-823
12. Ott S. Should women get screening bone mass measurements?. Ann Int Med 104 (1986) 874-876
13. Melton III L.J., Eddy D.M., and Johnston Jr. C.C. Screening for osteoporosis. Ann Intl Med 112 (1990) 516-528
14. Kanis JA. Screening for postmenopausal osteoporosis. A review for the Department of Health, London. 1992.
15. Royal College of Physicians. Osteoporosis: clinical guidelines for the prevention and treatment (1999), Royal College of Physicians, London
16. Royal College of Physicians and Bone and Tooth Society of Great Britain. Update on pharmacological interventions and an algorithm for management 2000 (2000), Royal College of Physicians, London UK
17. European Community. Report on osteoporosis in the European Community. Strasbourg, EC, 1998
18. Kanis J.A., Johnell O., Oden A., et al. Ten-year risk of osteoporotic fracture and the effects of risk factors on screening strategies. Bone 30 (2002) 251-258
19. World Health Organization. Prevention and management of osteoporosis. WHO Technical Report Series, No 921 (2003), WHO, Geneva
20. Barrett-Connor E., Gore R., Browner W.S., and Cummings S.R. Prevention of osteoporotic hip fracture: global versus high-risk strategies. Osteoporos Int 8 Suppl 1 (1998) S2-S7
21. Torgerson D.J., Thomas R.E., Campbell M.K., and Reid D.M. Randomized trial of osteoporosis screening. Arch Int Med 157 (1997) 2121-2125
22. Black D. Why elderly women should be screened and treated to prevent osteoporosis. Am J Med 98 suppl 2A (1995) 67S-75S
23. Kanis J.A., Dawson A., Oden A., et al. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12 (2001) 356-361
24. Torgerson D.J., and Kanis J.A. Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. Quart J Med 88 (1995) 135-139
25. National Osteoporosis Foundation (NOF). Physician's Guide to prevention and treatment of osteoporosis (2003), National Osteoporosis Foundation, Washington, DC
26. US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women (2003), Office of Disease Prevention and Health Promotion, Washington DC
27. US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Annals of Internal Medicine 137 (2002) 526-528
28. Lewiecki E.M., Watts N.B., McClung M.R., et al., For the International Society for Clinical Densitometry. Official position of the International Society for Clinical Densitometry. J Clin Endocrinol Metab 89 (2004) 3651-3655
29. Cheung A.M., Feig D.S., Kapral M., et al. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from The Canadian Task Force on Preventive Health Care. Can Med Assoc J 170 (2004) 1-9
30. Osteoporose: Tweede Herziene Richtlijn. website English summary published in Pols HA, Wittenberg J. CBO guideline "Osteoporosis" (second version). NTVG Ned Tijdschr Geneeskd2002 (2002). www.cbo.nl/product/richtlijnen/folder20021023121843/article2002111816584 7/pdf/osteoporose ;146:1359-63
31. Kanis J.A., Delmas P., Burckhardt P., Cooper C., et al., on behalf of the European Foundation for Osteoporosis and Bone Disease. Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7 (1997) 390-406
32. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002 (1929-1936) 359
33. Royal College of Physicians. Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians (2002), Royal College of Physicians, London UK
34. National Osteoporosis Foundation. Analysis of the effectiveness and cost of screening and treatment strategies for osteoporosis. A basis for development of practice guidelines. Osteoporos Int 8 suppl 4 (1998) 1-88
35. National Osteoporosis Foundation. Physicians guide to prevention and treatment of osteoporosis (1998), Excerpta Medica, Washington
36. Kanis J.A., Burlet N., Cooper C., et al., On behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19 (2008) 399-428
37. Kanis J.A., Adams J., Borgström F., et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42 (2008) 4-15
38. World Health Organization. Assessment of osteoporosis at the primary health care level. Summary Report of a WHO Scientific Group. WHO (2007), WHO, Geneva. www.who.int/chp/topics/rheumatic/en/index.html
39. Kanis J.A., Oden A., Johnell O., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18 (2007) 1033-1046
40. Kanis J.A., McCloskey E.V., Johansson H., et al. Case finding for the management of osteoporosis with FRAX® - Assessment and intervention thresholds for the UK. Osteoporos Int;19:1395-1408. Erratum in Osteoporos Int 20 (2009) 499-502
41. Siminoski K., Leslie W.D., Frame H., et al. Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 10 (2007) 120-123
42. Fujiwara S., Nakamura T., Orimo H., et al. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™). Osteoporos Int 19 (2008) 429-448
43. Kurth A.A., and Pfeilschifter J. [Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006]. Orthopade 36 (2007) 683-690 German
44. Dawson-Hughes B., Tosteson A.N., Melton III L.J., et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19 (2008) 449-458
45. Siris E., and Delmas P.D. Assessment of 10-year absolute risk: a new paradigm with worldwide application. Osteoporos Int 19 (2008) 383-384
46. Kanis J.A., Stevenson M., McCloskey E.V., et al. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility. analysis. Health Technol Assess 11 (2007) 1-256
47. Kanis J.A., Johnell O., and on behalf of the Committee of Scientific Advisors of the International Osteoporosis Foundation. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16 (2005) 229-238
48. Johansson H., Oden A., Johnell O., et al. Optimisation of BMD measurements to identify high risk groups for treatment - A test analysis. J Bone Miner Res 19 (2004) 906-913
49. Compston J., Cooper A., Cooper C., et al., On behalf of the National Osteoporosis Guideline Group (NOGG). Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK (2009), Maturitas. Maturitas 62:105-108
50. National Osteoporosis Guideline Group on behalf of the Bone Research Society. British Geriatrics Society, British Society of Rheumatology, Society of Endocrinology, British Orthopaedic Association, Primary Care Rheumatology Society, Osteoporosis 2000 and Osteoporosis Dorset. Osteoporosis: Clinical guideline for prevention and treatment (2008), UK. University of Sheffield Press, Sheffield
51. Orimo H., Sugioka Y., Fukunaga M., et al. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16 (1998) 139-150
52. Looker A.C., Wahner H.W., Dunn W.L., et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporosis Int 8 (1998) 468-489
53. Czerwiński E., Badurski J.E., Marcinowska-Suchowierska E., and Osieleniec J. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil 9 (2007) 337-356
54. Tsang S.W.Y., Kung A.W.C., Kanis J.A., et al. Ten-year fracture probability in Hong Kong southern Chinese according to age and BMD femoral neck T-scores. Osteoporos Int (2009 Mar 27.) [Epub ahead of print] PMID: 19326036
55. Lippuner K., Johansson H., Kanis J.A., and Rizzoli R. Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 20 (2009) 1131-1140
56. Eichler H.G., Kong S.X., Gerth, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 7 (2004) 518-528
57. Kanis J.A., and Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int 13 (2002) 765-767
58. Kanis J.A., Brazier J.E., Stevenson M., et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6 (2002) 1-146
59. National Institute for Health and Clinical Excellence. Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (2008), NICE, London
60. National Institute for Health and Clinical Excellence. Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (2008), NICE, London
61. Kanis J.A., Borgstrom F., Zethraeus N., et al. Intervention thresholds for osteoporosis in the UK. Bone 36 (2005) 22-32
62. Kanis J.A., Johnell O., Oden A., et al. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16 (2005) 6-14
63. Borgstrom F., Johnell O., Kanis J.A., et al. At what hip fracture risk is it cost-effective to treat? International Intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17 (2006) 1459-1471
64. Tosteson A.N., Melton III L.J., Dawson-Hughes B., et al. National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19 (2008) 437-447
65. National Osteoporosis Foundation (NOF). Clinician's Guide to prevention and treatment of osteoporosis (2008), DC National Osteoporosis Foundation, Washington
66. Kanis J.A., Black D., Cooper C., et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13 (2002) 527-536
67. Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2 (Nov 2006), CHMP, London
68. Cranney A., Wells G., Willan A., et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23 (2002) 508-516
69. Tosteson A.N., Jonsson B., Grima D.T., et al. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12 (2001) 849-857
70. Kanis J.A., Johnell O., Oden A., et al. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19 (2008) 385-397
71. Borgström F, Strom O, Coelho J et al. The cost-effectiveness of risedronate in the UK for the management of osteoporosis. 2008 Submited, Feb 09.